|
|
|
| Effect of Shenqi Huayu Formula combined with transcatheter arterial chemoembolization in the treatment of patients with primary hepatocellular carcinoma |
| LU Dongyan YE Xiaowei |
Department of Oncology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China
|
|
|
|
Abstract Objective To evaluate the effect of Shenqi Huayu Formula combined with transcatheter arterial chemoembolization (TACE) in the treatment of patients with primary hepatocellular carcinoma (PHC). Methods Sixty patients with PHC admitted to the First Affiliated Hospital, Guangzhou University of Chinese Medicine from June 2020 to December 2021 were selected and divided into control group and treatment group by random number table method, with 30 cases in each group. Both groups received TACE and postoperative symptomatic treatment, and the treatment group was additionally given Shenqi Huayu Formula. The efficacy of solid tumor in the two groups after four weeks of treatment was evaluated according to the response evaluation criteria in solid tumor 1.1. Traditional Chinese medicine syndrome scores, quality of life- liver cancer scale scores, the levels of serum alpha-fetoprotein (AFP), interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α) were compared between the two groups before and four weeks after treatment. Results After four weeks of treatment, there was no significant difference in clinical efficacy between the two groups (P＞0.05). After four weeks of treatment, the scores of hypochondriac pain, abdominal distension, nausea and vomiting, anorexia, spiritlessness and fatigue, and total scores in two groups were lower than those before treatment, and the score of fever was higher than that before treatment, and all syndrome scores and total scores in the treatment group were lower than those in the control group (P＜0.05). After four weeks of treatment, physical function, mental function, symptoms scores, and total scores in both groups were higher than those before treatment, and the treatment group was higher than the control group (P＜0.05). After four weeks of treatment, the levels of serum AFP, IL-6, IL-1β, and TNF-α in two groups were lower than those before treatment, and the treatment group was lower than the control group (P＜0.05). Conclusion Shenqi Huayu Formula combined with TACE can effectively reduce the clinical symptoms of PHC patients, improve their quality of life, and reduce the levels of serum AFP and inflammatory factors.
|
|
|
|
|
|
[1] 郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2019，41（1）：19-28.
[2] 党志博，李玲孺，李玲，等.基于虚毒瘀理论探讨原发性肝癌的治疗[J].中国医药导报，2021，18（7）：126-129.
[3] 李正军，梁定，张元朝，等.小柴胡汤合六味地黄汤加减防治原发性肝癌TACE术后栓塞后综合征50例临床研究[J].江苏中医药，2020，52（5）：38-40.
[4] 胡鸿涛，陈呈世，黎海亮，等.三氧化二砷联合索拉非尼及肝动脉化疗栓塞治疗难治性肝细胞癌肺转移[J].中华肿瘤杂志，2015，37（12）：942-943.
[5] 董安楠，李旺，吴方明，等.细胞因子诱导杀伤细胞免疫联合微创介入治疗早期肝癌的长期临床疗效观察[J].中华医学杂志，2015，95（33）：2668-2672.
[6] 覃文办，李永标，唐超莉，等.TACE联合替吉奥治疗原发性肝癌的近期疗效、毒副作用及生存情况观察[J].中国医药导报，2017，14（23）：71-79.
[7] 中华医学会.临床诊疗指南肾脏病学分册[M].北京：人民卫生出版社，2011：32-33.
[8] 侯帅，樊琳琳，戴光荣.非手术治疗原发性肝癌研究进展[J].实用肝脏病杂志，2016，19（2）：249-252.
[9] 杨海宁，翟孟昊，杨国旺.原发性肝癌栓塞后综合征的中西医治疗现况[J].北京中医药，2017，36（11）：1044-1048.
[10] 刘钊，李智，杨凯仑，等.原发性肝癌经肝动脉化疗栓塞术后短期病死率及死因分析[J].临床肝胆病杂志，2022， 38（11）：2510-2513.
[11] 沈诗彦，孙彩珍，陈灵仙，等.软肝消结方对中晚期原发性肝癌治疗作用的临床研究[J].中国医药科学，2022， 12（5）：87-90.
[12] 张恺，严卿莹，阮善明，等.中医药联合肝动脉化疗栓塞术治疗中晚期原发性肝癌的Meta分析[J].浙江中医药大学学报，2015，39（2）：84-91.
[13] 王清云.肝癌与情志关系[J].吉林中医药，2004，24（8）：47-47.
[14] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范（2019年版）[J].中国实用外科杂志，2020，40（2）：121-138.
[15] 王垒，曾建兴，陈振伟，等.基于大数据平台的肝细胞癌自动化中国分期模型研究[J].中华肝脏外科手术学电子杂志，2020，9（2）：148-152.
[16] Forner A，Ayuso C，Varela M，et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma：are response evaluation criteria [J]. Cancer，2009， 115（3）：616-623.
[17] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：211-212.
[18] Wan C，Fang J，Yang Z，et al. Development and validation of a quality of life instrument for patients with liver Cancer QOL-LC [J]. Am J Clin Oncol，2010，33（5）：448-455.
[19] Ye X，Lu D，Chen X，et al. A Multicenter，Randomized，Double-Blind，Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain [J]. J Pain Symptom Manag，2016，51（6）：979-986.
[20] 王磊，周荣耀，高月求.中医研究肝癌概况[J].中西医结合肝病杂志，2014，24（3）：186-189.
[21] 谢君艳，邓小敏，陈国忠，等.新思路探析“见肝之病，知肝传脾，当先实脾”[J].辽宁中医药大学学报，2018，20（6）：85-87.
[22] 倪育淳，赵红艳.周岱翰教授运用下瘀血汤加味治疗肝癌的临床经验介绍[J].新中医，2009，41（5）：8-10.
[23] 李朝军，刘嘉湘.刘嘉湘教授治疗肝癌经验[J].山西中医，2009，25（12）：9-10.
[24] 刘庆，岳小强，侯凤刚，等.血瘀证与肝癌关系浅析——附1010篇（本）相关文献分析[J].山东中医药大学学报，2003，27（2）：92-94.
[25] 李秀惠，袁慧鑫.从病因病机入手提高中医药治疗原发性肝癌的疗效[J].临床肝胆病杂志，2021，37（9）：2001- 2004.
[26] 王俊镔.参芪化瘀方对原发性肝癌血瘀证血液流变学影响的临床观察[D].广州：广州中医药大学，2019.
[27] 蒋锐沅，满婷婷，覃艳春，等.敷和备化方联合TACE术对原发性肝癌患者血清炎性因子及临床疗效观察[J].中国中医基础医学杂志，2021，1（27）：102-107. |
|
|
|
